Looks like people are already warming up for tomorrow's Open Access Day. In the Guardian, Richard Smith pens a column on Springer's acquisition of BioMed Central, which he says may turn out to be a pivotal moment in the history of scientific publishing. "I'm no seer, but it became obvious to me in the mid-90s, when ... I was the chief executive of the BMJ Publishing Group, that the transition to open access would have to happen," he writes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.